Paratek Pharmaceuticals (NASDAQ:PRTK) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a hold rating in a research note issued to investors on Thursday, ValuEngine reports.

A number of other equities research analysts have also recently commented on the company. Wedbush reissued an outperform rating and set a $12.00 price target (down from $17.00) on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. Zacks Investment Research cut Paratek Pharmaceuticals from a hold rating to a sell rating in a report on Friday, July 26th. LADENBURG THALM/SH SH reissued a buy rating on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. Finally, HC Wainwright reissued a buy rating on shares of Paratek Pharmaceuticals in a report on Wednesday, June 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Paratek Pharmaceuticals has an average rating of Hold and a consensus price target of $23.71.

NASDAQ PRTK traded down $0.03 on Thursday, hitting $3.08. 241,918 shares of the company traded hands, compared to its average volume of 298,548. The company has a quick ratio of 13.95, a current ratio of 14.06 and a debt-to-equity ratio of 14.48. The business has a 50 day simple moving average of $3.61. The firm has a market cap of $99.84 million, a P/E ratio of -0.86 and a beta of 1.75. Paratek Pharmaceuticals has a 52-week low of $2.87 and a 52-week high of $12.30.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.19) by $0.09. The business had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.89 million. Paratek Pharmaceuticals had a negative return on equity of 232.61% and a negative net margin of 642.70%. As a group, analysts anticipate that Paratek Pharmaceuticals will post -4.4 EPS for the current year.

Large investors have recently bought and sold shares of the business. Norges Bank bought a new stake in shares of Paratek Pharmaceuticals in the fourth quarter worth about $2,447,000. Trellus Management Company LLC increased its holdings in shares of Paratek Pharmaceuticals by 65.0% in the second quarter. Trellus Management Company LLC now owns 165,000 shares of the specialty pharmaceutical company’s stock worth $658,000 after purchasing an additional 65,000 shares during the last quarter. Water Island Capital LLC increased its holdings in shares of Paratek Pharmaceuticals by 15.1% in the first quarter. Water Island Capital LLC now owns 366,648 shares of the specialty pharmaceutical company’s stock worth $1,965,000 after purchasing an additional 48,130 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Paratek Pharmaceuticals by 16.9% in the fourth quarter. Deutsche Bank AG now owns 316,661 shares of the specialty pharmaceutical company’s stock worth $1,624,000 after purchasing an additional 45,777 shares during the last quarter. Finally, Stifel Financial Corp bought a new stake in shares of Paratek Pharmaceuticals in the fourth quarter worth about $90,000. 75.00% of the stock is currently owned by institutional investors and hedge funds.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Further Reading: How are institutional investors different from individual investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.